JNJ241220P149000
- 3.40
- -1.76-34.11%
Johnson & Johnson Newsroom
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Johnson & Johnson Analyst Ratings
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Cuts Target Price to $175
Johnson & Johnson Analyst Ratings
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $166
Johnson & Johnson's M&A Strategy in Cardiovascular Devices Supports Hold Rating
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
Johnson & Johnson Initiated at Outperform by Wolfe Research
Johnson & Johnson Analyst Ratings
Wolfe Research Upgrades Johnson & Johnson(JNJ.US) to Buy Rating, Raises Target Price to $190
Johnson & Johnson Analyst Ratings
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $162
Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating
Daiwa Securities Adjusts Price Target on Johnson & Johnson to $170 From $150, Maintains Neutral Rating
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $185
Goldman Sachs Lowers Price Target on Johnson & Johnson to $159 From $162
Johnson & Johnson Price Target Raised to $166.00/Share From $163.00 by Wells Fargo
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $215
Johnson & Johnson Is Maintained at Outperform by RBC Capital